Bronchiectasis
Drug research and approvals for bronchiectasis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 17, 2026, 94 studies of bronchiectasis are recruiting on ClinicalTrials.gov, Health Canada has authorized 11 drug trials for it since 2013, FDA has 1 approved and 8 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 94
- Trials authorized in Canada: 11
- FDA orphan approvals: 1
- EU medicines: 1
Recruiting Now
Newest start dates first, of 94 recruiting on ClinicalTrials.gov ↗- Chronic Respiratory Disease Participant Engagement StudyNCT07924462 · Not reported · Richmond Research Institute · starts Nov 1, 2026
- THERMotherapy Against Persistent Bacterial LUNG InfectionsNCT05351242 · Not applicable · Chronic Obstructive Pulmonary Disease Trial Network, Denmark · starts Oct 14, 2026
- Itraconazole Therapy In Bronchiectasis With Airway MoldNCT07283497 · Phase 4 · Mayo Clinic · starts Aug 17, 2026
- Phase 1 Study to Assess the Effects of HSK31858 on the QT/QTc Interval in Healthy Chinese ParticipantsNCT07915024 · Phase 1 · Haisco Pharmaceutical Group Co., Ltd. · starts Aug 6, 2026
- A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With…NCT07720375 · Phase 2 · UCB Biopharma SRL · starts Aug 5, 2026
- T2AIR: Real-World Efficacy and Safety of Biologics Targeting Type 2 Inflammation in Asthma and COPDNCT07823842 · Not reported · Shanghai Pulmonary Hospital, Shanghai, China · starts Jul 30, 2026
- Primary Ciliary Dyskinesia in Adult BronchiectasisNCT07566611 · Not applicable · Indiana University · starts Jul 17, 2026
- Tele-Pulmonary Rehabilitation For Patients With Chronic Lung DiseasesNCT07666841 · Not applicable · Tel-Aviv Sourasky Medical Center · starts Jul 1, 2026
- Azithromycin to Modify Bronchiectasis Exacerbation RiskNCT07608328 · Phase 4 · Assiut University · starts Jun 29, 2026
- A Study of AZD0292 in Chinese Participants With Bronchiectasis and Chronic Pseudomonas Aeruginosa ColonizationNCT07774403 · Phase 2 · AstraZeneca · starts Jun 24, 2026
Drug Pipeline
9 in phase 3, 3 in phase 2, 3 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition- Ciprofloxacin
- Phase 3 Bacterial DNA gyrase inhibitor
- Roflumilast
- Phase 3 Phosphodiesterase 4 inhibitor
- Mannitol
- Phase 3 Unknown
- Azithromycin
- Phase 3 Bacterial 70S ribosome inhibitor
- Brensocatib
- Phase 3 Dipeptidyl peptidase I inhibitor
- Itraconazole
- Phase 3 Cytochrome P450 51 inhibitor
- Beclomethasone dipropionate
- Phase 3 Glucocorticoid receptor agonist
- Formoterol
- Phase 3 Beta-2 adrenergic receptor agonist
- Carbocysteine
- Phase 3 Unknown
- Tobramycin
- Phase 2 70S ribosome inhibitor
- Aztreonam
- Phase 2 Bacterial penicillin-binding protein inhibitor
- Alvelestat
- Phase 2 Leukocyte elastase inhibitor
- Human immunoglobulin g
- Phase 1 Replacement therapy, immunomodulatory effects
- ALX-009
- Phase 1
- Icenticaftor
- Phase 1 Cystic fibrosis transmembrane conductance regulator activator
How Its Trials Ended
330 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 60 whose ending is known, 45% met their primary endpoint, 8% missed it and 47% stopped early.
- Completed, result not reported11836%
- Ongoing7723%
- Status unknown7523%
- Met its primary endpoint278%
- Stopped: other or unclear155%
- Missed its primary endpoint52%
- Stopped: lack of efficacy31%
- Stopped: enrollment or feasibility31%
- Stopped: sponsor or business decision31%
- Stopped: funding31%
- Stopped: safety10%
Trials Authorized in Canada
The 10 newest of 11; search them all in Canada trials| Nov 10, 2026 | A phase 2b, multicenter, randomized, double-blind, parallel-group, placebo-controlled, dose range finding study to evaluate the efficacy, safety, and…CSL787 | CSL | Pending |
| Mar 20, 2026 | A randomized, double-blinded, placebo-controlled, parallel-group, phase 2a participants with non-cystic fibrosis bronchiectasis (ncfb) study to assess the…SAR445399 | Sanofi-Aventis Canada Inc | Ongoing |
| Aug 21, 2025 | A phase IIb randomized, double-blind, placebo-controlled, parallel, multidose study to evaluate the efficacy, safety, and pk of azd0292 in participants 12…AZD0292 | AstraZeneca Pharmaceuticals LP | Ongoing |
| Apr 15, 2025 | A phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of bi 1291583 2.5 mg administered once daily…Verducatib (bi 1291583) | Boehringer Ingelheim (Canada) Ltd Ltee | Ongoing |
| Feb 28, 2024 | A randomized, double-blind, placebo-controlled, parallel group, proof-ofconcept (poc) study to assess the efficacy, safety and tolerability of itepekimab, in…Itepekimab (SAR440340; REGN3500) | Sanofi-Aventis Canada Inc | Closed |
| May 16, 2023 | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of bi 1291583 q.d. in patients with…BI 1291583 | Boehringer Ingelheim (Canada) Ltd Ltee | Ongoing |
| Feb 4, 2021 | A multicentre, randomised, double-blind, parallel-group, placebo-controlled, 52 week, phase III study with an open-label extension to evaluate the efficacy and…Benralizumab (MEDI-563) | AstraZeneca Pharmaceuticals LP | Ongoing |
| Dec 3, 2020 | A phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of brensocatib administered once daily for 52…Brensocatib (INS1007) | Insmed | Closed |
| Jan 31, 2018 | A double-blind, placebo controlled, multi-center, clinical trial to investigate the efficacy and safety of 12 months of therapy with inhaled promixin®…Colistimethate | Zambon | Closed |
| Apr 17, 2014 | A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of pulmaquin® in the management of chronic lung…Pulmaquin | Aradigm Corp. | Closed |
FDA Orphan Designations
Approved first, then open designations, newest first| Oct 30, 2020 | Bronchitol®As add-on maintenance therapy to improve pulmonary function in adult patients 18 years of age and older with cystic fibrosis. Use… | Pharmaxis Europe Limited | Approved |
| Feb 14, 2014 | DoxofyllineTreatment of bronchiectasis | Alitair Pharmaceuticals, Inc. | Designated |
| Dec 20, 2013 | ErdosteineTreatment of bronchiectasis | Edmond Pharma S.r.l. | Designated |
| Jun 1, 2011 | CiprofloxacinThe management of bronchiectasis | Savara Inc. | Designated |
| Apr 3, 2008 | Alpha1-antitrypsin(human)Treatment of bronchiectasis | Kamada Ltd. | Designated |
| Dec 27, 2006 | Liposomal ciprofloxacin for inhalationManagement of bronchiectasis | Savara Inc. | Designated |
| Aug 28, 2001 | Recombinant human alpha-1 antitrypsin (rAAT)To delay progression of chronic obstructive pulmonary disease resulting from AAT deficiency-mediated emphysema and bronchiectasis | AiroMedica LLC | Designated |
| Jun 18, 1999 | TobramycinTreatment of bronchiectasis patients infected with Pseudomonas aeruginosa. | Novartis Pharmaceuticals Corp. | Designated |
| Mar 6, 1995 | Recombinant human gelsolinTreatment of acute and chronic respiratory symptoms of bronchiectasis. | BioAgeis, Therapeutics, Inc. | Designated |
Medicines Authorised in the EU
Newest first| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Nov 18, 2025 | BrinsupriBrensocatib | Insmed Netherlands B.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA